Bristol-Myers Squibb Company (BMY) Stock Forecast
BMY analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.50 / 5 from 28 analysts
- Price target
- $65.62 average of analyst targets
- Upside to target
- +9.8% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $1.28
- 52-week range
- $42.60 – $68.09
BMY analyst ratings
28 analystsNumber of analysts at each rating.
BMY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BMY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.33 | $0.98 | $1.87 | $1.63 | −18.4% | 23 |
| Current fiscal year (2026) | $6.62 | $6.15 | $7.05 | $6.15 | +7.6% | 27 |
| Next fiscal year (2027) | $6.61 | $6.04 | $7.74 | $6.62 | −0.1% | 26 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BMY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $12.73B | $12.50B | $13.12B | +4.2% | 21 |
| Current fiscal year (2026) | $49.88B | $49.17B | $50.20B | +3.5% | 26 |
| Next fiscal year (2027) | $48.48B | $46.78B | $50.44B | −2.8% | 25 |
BMY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BMY revenue: reported and forecast
BMY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.61 | $1.73 | $1.73 | $1.52 | $1.33 | −17.5% | 1 up · 8 down |
| Current fiscal year (2026) | $6.34 | $6.95 | $6.95 | $6.77 | $6.62 | +4.4% | 1 up · 8 down |
| Next fiscal year (2027) | $6.20 | $6.56 | $6.56 | $6.60 | $6.61 | +6.7% | 8 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BMY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BMY beat in 11 of 12.
What analysts expect from BMY
28 analysts cover Bristol Myers Squibb; their consensus rating is buy (3.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $65.62, 9.8% above the latest close of $59.75. Analysts expect earnings of $6.62 per share for 2026, +7.6% from a year earlier. For 2027 the average estimate is $6.61 per share on revenue of $48.5 billion. Bristol Myers Squibb beat the EPS estimate in 11 of the last 12 quarters.
Related: BMY income statement, BMY key metrics, BMY chart. See the BMY stock overview for the latest quote and news.
BMY forecast FAQ
What is Bristol Myers Squibb's price target?
The average analyst price target for Bristol Myers Squibb is $65.62, 9.8% above the latest close of $59.75.
Is Bristol Myers Squibb a buy, hold or sell?
Of 28 analysts covering Bristol Myers Squibb, 6 rate it a strong buy, 4 a buy, 17 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Bristol Myers Squibb's EPS forecast?
Analysts forecast $6.62 per share for 2026 (range $6.15 to $7.05); for 2027 the estimate is $6.61.
What is Bristol Myers Squibb's revenue forecast?
The average revenue estimate for 2026 is $49.9 billion, growth of 3.5%; for 2027 it is $48.5 billion.
When does Bristol Myers Squibb report earnings?
Bristol Myers Squibb is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens; the EPS estimate is $1.28.
Does Bristol Myers Squibb usually beat earnings estimates?
Bristol Myers Squibb reported EPS at or above the analyst estimate in 11 of the last 12 quarters.